KCIA
ALZN icon

Kingsbury Capital Investment Advisors’s Alzamend Neuro ALZN Stock Holding History

Kingsbury Capital Investment Advisors’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.59M Buy
1,329,100
+762,367
+135% +$845K 1.35% 18
2026
Q1 		$601K Buy
+566,733
New +$1.13M 0.56% 48
2022
Q3 		– Sell
-19
Closed -$22K – 78
2022
Q2 		$22K Buy
19
+10
+111% +$13K 0.03% 92
2022
Q1 		$14K Buy
+9
New +$16.9K 0.02% 97

Other funds holding ALZN

KWM
KMT Wealth Management El Segundo, California $118M AUM 26.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IA
IFG Advisory Atlanta, Georgia $2.85B AUM 26.07% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Kingsbury Capital Investment Advisors's ALZN Position: Q2 2026 in Review

Kingsbury Capital Investment Advisors increased its Alzamend Neuro (ALZN) stake by 135% in Q2 2026, buying an estimated $845K and bringing the position to 1,329,100 shares worth $1.59M. The position accounts for 1.35% of the portfolio, ranked #18.

Kingsbury Capital Investment Advisors first reported a position in ALZN in Q1 2022 and has held it in 4 quarters since. 12 funds tracked by Wall St. Rank hold ALZN as of Q2 2026.

  • Kingsbury Capital Investment Advisors held 1,329,100 shares of Alzamend Neuro worth $1.59M as of Q2 2026.
  • Kingsbury Capital Investment Advisors bought 762,367 Alzamend Neuro shares in Q2 2026, an estimated $845K.
  • Alzamend Neuro made up 1.35% of Kingsbury Capital Investment Advisors's portfolio in Q2 2026, its #18 holding.
  • Kingsbury Capital Investment Advisors first reported a position in Alzamend Neuro in Q1 2022 and has held it in 4 quarters since.
  • 12 funds tracked by Wall St. Rank held Alzamend Neuro as of Q2 2026.

Based on Kingsbury Capital Investment Advisors's 13F filing for Q2 2026, filed 25 Aug 2026.